Open access
Open access
Powered by Google Translator Translator

Pediatrics – Rheumatology

RCT | Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis.

15 Aug, 2022 | 12:05h | UTC

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial – Annals of Rheumatic Diseases

 


EULAR/ACR points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases.

24 Jun, 2022 | 11:23h | UTC

The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist – Annals of Rheumatic Diseases

 


EULAR/PRES recommendations for vaccination of pediatric patients with autoimmune inflammatory rheumatic diseases.

24 Jun, 2022 | 11:17h | UTC

EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021 – Annals of Rheumatic Diseases

 


Consensus Paper: Diagnosis and treat-to-target management of macrophage activation syndrome in children.

24 Jun, 2022 | 11:13h | UTC

Egyptian evidence-based consensus on clinical practice guidelines for the diagnosis and treat-to-target management of macrophage activation syndrome in children – Egyptian Rheumatology and Rehabilitation

 


Cohort Study: Association of maternal autoimmune diseases with risk of mental disorders in offspring in Denmark.

20 Apr, 2022 | 09:19h | UTC

Association of Maternal Autoimmune Diseases With Risk of Mental Disorders in Offspring in Denmark – JAMA Network Open

 

Commentary on Twitter

https://twitter.com/JAMANetworkOpen/status/1515057370715594753

 


RCT: Long-term efficacy and safety of up to 108 weeks of Ixekizumab in pediatric patients with moderate to severe plaque psoriasis.

18 Apr, 2022 | 09:49h | UTC

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial – JAMA Dermatology

Original Study: Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS) – British Journal of Dermatology

 

Commentary on Twitter

 


Cohort Study: Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection.

12 Apr, 2022 | 09:57h | UTC

Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection: a multicentre cohort study – Canadian Medical Association Journal

News Release: Children older than 5 at higher risk of COVID-19-related multisystem inflammatory syndrome – Canadian Medical Association Journal

Commentary: Older Kids More Vulnerable to MIS-C: Study – HealthDay

 


Acute phase of Kawasaki disease: a review of national guideline recommendations.

12 Apr, 2022 | 08:32h | UTC

Acute phase of Kawasaki disease: a review of national guideline recommendations – European Journal of Pediatrics

 


Systematic Review: Epidemiology of musculoskeletal manifestations in pediatric inflammatory bowel disease.

7 Apr, 2022 | 07:55h | UTC

Epidemiology of Musculoskeletal Manifestations in Pediatric Inflammatory Bowel Disease: A Systematic Review – ACR Open Rheumatology

 


BSR guideline on management of pediatric, adolescent and adult patients with idiopathic inflammatory myopathy.

4 Apr, 2022 | 01:05h | UTC

British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy – Rheumatology

 


Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.

1 Apr, 2022 | 08:45h | UTC

Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials – eBioMedicine

Commentary: Network meta-analysis rates treatments for Kawasaki disease – medwire News

 


Guideline: Treatment of unspecific back pain in children and adolescents.

29 Mar, 2022 | 09:52h | UTC

Treatment of Unspecific Back Pain in Children and Adolescents: Results of an Evidence-Based Interdisciplinary Guideline – Children

 


ACR/Vasculitis Foundation Guideline for the management of Kawasaki Disease.

9 Mar, 2022 | 10:01h | UTC

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease

 


ACR Guidelines for the Treatment of Juvenile Idiopathic Arthritis.

4 Mar, 2022 | 08:58h | UTC

News Release: The American College of Rheumatology releases two updated guidelines for treatment of juvenile idiopathic arthritis – American College of Rheumatology

 

2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging – Arthritis & Rheumatology

 

2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis

 


What’s New in Pediatric Orthopedics.

25 Feb, 2022 | 10:48h | UTC

What’s New in Pediatric Orthopaedics – The Journal of Bone & Joint Surgery

 


Anti-inflammatory treatment of Kawasaki Disease: comparison of current guidelines and perspectives.

25 Feb, 2022 | 10:29h | UTC

Anti-inflammatory Treatment of Kawasaki Disease: Comparison of Current Guidelines and Perspectives – Frontiers in Medicine

 


Review: Juvenile idiopathic arthritis.

28 Jan, 2022 | 08:13h | UTC

Juvenile idiopathic arthritis – Nature Reviews Disease Primers (if the link is paywalled, try this one)

Infographic: Juvenile idiopathic arthritis (if the link is paywalled, try this one)

 

Commentary on Twitter

 


Review: Treatment of multisystem inflammatory syndrome (MIS-C) in children and adolescents.

18 Jan, 2022 | 09:46h | UTC

Treatment of MIS-C in Children and Adolescents – Current Pediatrics Reports

See also: Clinical practice guidelines in multisystem inflammatory syndrome (MIS-C) related to COVID-19: a critical review and recommendations – World Journal of Pediatrics

Related:

Review of 4,470 cases of Multisystem Inflammatory Syndrome in Children in the US.

WHO issues guidelines on the treatment of children with multisystem inflammatory syndrome associated with COVID-19.

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2.

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

 


Systematic Review: Foot orthoses for treating pediatric flat feet.

18 Jan, 2022 | 09:16h | UTC

Foot orthoses for treating paediatric flat feet – Cochrane Library

Summary: Foot orthoses for treating flat feet in children – Cochrane Library

 


In a study with 1110 children with prolonged fever, MRP8/14 serum levels were validated as a diagnostic marker for systemic juvenile idiopathic arthritis.

14 Jan, 2022 | 08:07h | UTC

MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever – Rheumatology (link to abstract – $ for full-text)

Commentary: It is about time: the first validated biomarker for early diagnosis of sJIA – Rheumatology

 


Imaging in non-bacterial osteomyelitis in children and adolescents: diagnosis, differential diagnosis and follow-up—an educational review based on a literature survey and own clinical experiences.

6 Oct, 2021 | 08:43h | UTC

Imaging in non-bacterial osteomyelitis in children and adolescents: diagnosis, differential diagnosis and follow-up—an educational review based on a literature survey and own clinical experiences – Insights into Imaging

 


Opinion | Amplified Pain Syndrome—An Insupportable Assumption

10 Mar, 2021 | 08:13h | UTC

Amplified Pain Syndrome—An Insupportable Assumption – JAMA Pediatrics

 


Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

23 Feb, 2021 | 01:57h | UTC

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C) – Open Forum Infectious Diseases

Commentary: Experts at Children’s Hospital of Philadelphia Describe Types of Rashes Associated with MIS-C – Children’s Hospital of Philadelphia

 


SR: Multisystem inflammatory syndrome in children related to COVID-19

21 Feb, 2021 | 22:11h | UTC

Multisystem inflammatory syndrome in children related to COVID-19: a systematic review – European Journal of Pediatrics

 

Commentary on Twitter (thread – click for more)

 


Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

3 Feb, 2021 | 01:39h | UTC

Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children – JAMA

 

Commentaries on Twitter

 


Stay Updated in Your Specialty

No spam, just news.